April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Niraparib/Bevacizumab Combo Meets Safety and Tolerability Objectives
June 9th 2016It is feasible to administer the PARP inhibitor niraparib in combination with bevacizumab to patients with platinum-sensitive relapsed ovarian cancer with manageable toxicities. The results of a phase I study (NCT02354131) in 12 patients were presented during a poster session at the 2016 ASCO Annual Meeting.
Read More
First-in-class "Stemness" Inhibitor Napabucasin Shows Promise in Advanced Ovarian Cancer
June 9th 2016Napabucasin (BBI-608, BB608) is a first-in-class cancer "stemness" inhibitor that targets the STAT3 pathway, has acceptable toxicity, and shows some antitumor activity in combination with paclitaxel in platinum-resistant ovarian cancer. Results of an early phase trial were presented at a poster session at the 2016 ASCO Annual Meeting.
Read More
Avelumab Shows Promise in Early Trial in Advanced Ovarian Cancer
June 9th 2016Avelumab (MSB0010718C), a fully human anti-PD-L1 (programmed death-1 receptor ligand) IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with acceptable toxicity in the phase Ib JAVELIN Solid Tumor trial.
Read More
Olaparib Extends OS in Relapsed Ovarian Cancer
June 8th 2016The PARP inhibitor olaparib (Lynparza) significantly increased overall survival (OS) in women with platinum-sensitive relapsed serous ovarian cancer when given as maintenance monotherapy. These interim results, a third updated survival analysis, come from an extension of the Study 19 phase II trial and were presented at the 2016 ASCO Annual Meeting.
Read More
Durvalumab Combos Tested in Women's Cancers, and to be Tested in Basket Trial
June 8th 2016Durvalumab, an investigational PD-L1 targeting drug, is the subject of a unique ongoing basket trial being conducted by the National Institutes of Health, and was part of a single arm phase I combination therapy study of the drug in 19 patients with cervical cancer, triple negative breast cancer (TNBC), ovarian cancer, or uterine leiomyosarcoma.
Read More
Black Women Less Likely to Pursue BRCA Testing and Cancer Risk Reduction Measures
June 8th 2016Findings from a population-based study reported at the 2016 ASCO Annual Meeting revealed that young black women with breast cancer are much less likely to undergo testing for the BRCA gene or to get risk reducing prophylactic mastectomy or salpingo-oophorectomy than other women.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Blinatumomab Granted Priority Review for Pediatric ALL
May 5th 2016The FDA has granted a priority review to a supplemental biologics license application that would extend the indication for blinatumomab to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Read More
IP Therapy Proves Non-Superior to IV/Bevacizumab Combination in Ovarian Cancer
April 26th 2016Intraperitoneal (IP) therapy was not superior to intravenous (IV) treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer, according to phase III findings from the GOG-252 study.
Read More
Telotristat Etiprate Application for Carcinoid Syndrome Submitted to FDA
March 31st 2016A new drug application (NDA) has been submitted to the FDA for telotristat etiprate as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs), according to a statement from the drug's developer, Lexicon Pharmaceuticals.
Read More
FDA Approves Defibrotide in Hepatic VOD Post-Stem Cell Transplantation
March 31st 2016The FDA has approved defibrotide sodium (Defitelio) as a treatment for severe hepatic veno-occlusive disease (VOD) with associated kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT), based on data from the collection of 3 studies.
Read More
Benefits Observed with Second-Line Therapy in Metastatic Pancreatic Cancer
March 30th 2016Second-line treatment of metastatic pancreatic cancer, after first-line treatment with nab-paclitaxel plus gemcitabine or gemcitabine alone, is feasible and may improve outcomes, according to a post-hoc analysis of the phase 3 MPACT trial presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
Trabectedin Expands Treatment Paradigm in Uterine Leiomyosarcoma
March 26th 2016A subgroup analysis of the phase III SAR-3007 trial demonstrating the efficacy of trabectedin (Yondelis) in patients with advanced uterine leiomyosarcoma bodes well for the malignancy's armamentarium, according to Martee L. Hensley, MD.
Read More
Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian Cancer
March 24th 2016Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.
Watch
Correlation Drawn Between Homologous Recombination and Longer Survival in Ovarian Cancer
March 23rd 2016Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival versus patients without HR mutations, according to a mutational analysis of the phase III GOG 218 study.
Read More
Dr. John Hays on Gynecologic Cancer Mutations and Choosing the Right Treatment
March 22nd 2016Hays says current genetic testing gives oncologists a wide variety of information that may make choosing the correct treatment "a little more difficult." Hays adds that within the current treatment paradigm of gynecologic cancer, oncologists are mainly focusing on BRCA mutations.
Watch
PARP Inhibitors Opening New Doors in Ovarian Cancer
March 22nd 2016Researchers are now working on refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities. For expert insight on these topics, Targeted Oncology sat down with Shannon Westin, MD.
Read More
Tumor Growth and Angiogenesis in Ovarian Cancer Linked to Key Adapter Protein
January 20th 2016Results from The Cancer Genome Atlas (TCGA) have shown that alterations in gene copy number (ie, amplifications or deletions) are an important characteristic of high-grade serous ovarian cancers (HGSOC).
Read More
CT-Planned, High-Dose-Rate Brachytherapy Shows Local Control, Survival Benefit in Cervical Cancer
January 2nd 2016The use of computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT) demonstrated excellent local control (LC) and survival for patients with stage I/II cervical carcinoma.
Read More